Clinical Study

D4194c00008- Prospective, Interventional Pilot Study Of Mobile Devices And Digital Applications To Detect Early Pneumonitis And Other Pulmonary Adverse Events In Unresectable Stage III Non-Small Cell Lung Cancer Patients On Durvalumab

Posted Date: Apr 28, 2021

  • Investigator: Muhammad Riaz
  • Specialties: Cancer, Lung Cancer, Oncology
  • Type of Study: Observational/Survey

The primary goal of this study is to determine whether mobile devices can improve the detection of pulmonary AEs (including pneumonitis) in stage III NSCLC patients post-CRT, while on durvalumab.

Criteria:

Has Unresectable Stage Iii Nsclc That Has Not Progressed Following Concurrent Platinum-Based Chemotherapy And Radiation Therapy And Is Eligible To Receive Durvalumab, No Supplemental Oxygen Dependency, No Comorbidities That Will Prevent Consistent And Reliable Measurement Assessments With Multiparametric Mobile Technology Including Severe Chronic Obstructive Pulmonary Disorder (Copd), Severe Asthma, Congestive Heart Failure [Chf], Interstitial Lung Disease [Ild], And Others, No Current Immunotherapy, No History Of Autoimmune Disease

Keywords:

Lung Cancer, Nsclc

For More Information:

Uc Cancer Center
513-584-7658
cancer@uchealth.com